A Phase 2 interventional study of plecanatide and Placebo in Functional Constipation (FC), sponsored by Bausch Health Americas, Inc.. Active, not recruiting at 29 sites in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing plecanatide in Constipation — none open to participants now, 1 under way, none of them phase 3. plecanatide · Constipation.
Among the 12 studies testing plecanatide in Constipation, this one is the 10th largest by planned enrollment, is the only one that started in 2026, is one of 5 in phase 2, and was the 12th registered.
1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.
Browse Constipation studies →None of the 12 studies testing plecanatide in Constipation is open now. The open studies under Constipation, anywhere →
plecanatide: first FDA approval 2017 (TRULANCE). What it is approved for, and how studies give it, is on its page →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 7
First in 2010; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 180 is above the median of 75 across 885 interventional studies indexed under Constipation.
Median enrollment 800 across the 12 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 2 most frequent:
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
21 studies in Constipation by Bausch Health Companies Inc.: none open now, 1 under way, none of them phase 3. Of 20 finished, 15 (75%) have results posted.
Among the 21 studies in Constipation by Bausch Health Companies Inc., this one is the 13th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2026, is one of 9 in phase 2, and was the 21st registered.
Bausch Health Companies Inc.’s Constipation studies by the year they started, since 2006.
1 of the studies testing plecanatide in Constipation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07723924Bausch Health Americas, Inc.This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC | 2027-10-18 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing plecanatide in Constipation, from their registry updates:
Among Bausch Health Companies Inc.’s 21 in Constipation:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if plecanatide can treat functional constipation in children and adolescents aged 6 to less than 18 years. It will also learn about the safety and pharmacokinetics of plecanatide in this population. The main questions it aims to answer are:
Participants will:
This Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study is designed to evaluate the efficacy, safety, and pharmacokinetics (PK) of plecanatide administered orally once daily in pediatric participants with functional constipation (FC). Approximately 180 participants will be enrolled at up to 30 investigational sites in the United States and randomized in a 1:1:1 ratio to receive low-dose plecanatide, high-dose plecanatide, or matching placebo. Randomization will be stratified by age group (6 to 11 years and 12 to less than 18 years) and sex.
Background and Rationale Functional constipation is a common condition in children and adolescents and is characterized by infrequent bowel movements, hard stool consistency, and associated symptoms such as straining and abdominal discomfort. Available treatment options in the pediatric population are limited, and there remains a need for additional therapies.
Plecanatide is an orally administered guanylate cyclase-C (GC-C) agonist that acts locally in the gastrointestinal tract to increase intestinal fluid secretion and transit. Clinical studies in adults with chronic idiopathic constipation have demonstrated improvements in bowel movement frequency and stool consistency, as well as an acceptable safety profile. The current study is designed to evaluate plecanatide in a pediatric population using a weight-based dosing approach intended to achieve exposure levels comparable to those associated with efficacy in adults.
Study Design The study consists of three periods: a Screening/Baseline Period, an 8-week Treatment Period, and a Post-treatment Follow-up Period. The total duration of participation is approximately 14 weeks (98 days).
During the Screening/Baseline Period (up to 28 days), participants and/or caregivers complete daily assessments using an electronic diary (eDiary) to record bowel movements, stool characteristics, and constipation-related symptoms. Data from the eDiary are used to establish baseline values and confirm eligibility prior to randomization.
Participants who meet all eligibility criteria are randomized on Day 1 and enter the Treatment Period. Study drug is administered once daily for 8 weeks. Participants are required to continue daily eDiary entries throughout the Treatment Period to capture bowel movement frequency, stool consistency, symptom severity, and use of rescue medication.
Following completion of the Treatment Period, participants enter a 2-week Post-treatment Follow-up Period, during which eDiary assessments continue. A final study visit is conducted at the end of follow-up.
Treatment and Randomization Participants are randomized via an interactive web-based system to receive low-dose plecanatide, high-dose plecanatide, or placebo. Dose assignment is based on treatment group and participant body weight at the time of randomization in order to achieve predefined weight-based dosing ranges.
Study drug is administered orally once daily, preferably in the morning, with or without food. Participants who are unable to swallow tablets may have the study drug administered in a suitable alternative form as described in the protocol.
A rescue medication (bisacodyl) is provided for use if a participant has not had a bowel movement for at least 72 hours. Use of rescue medication is recorded in the eDiary and is subject to protocol-defined limitations.
Efficacy Evaluations Efficacy evaluations are based primarily on data collected through the eDiary and participant-reported outcome (PRO) instruments administered at study visits.
The primary efficacy variable is the change from baseline in spontaneous bowel movement (SBM) frequency at Week 8. Secondary efficacy variables include responder endpoints based on SBM and complete spontaneous bowel movement (CSBM) frequency, stool consistency assessed using the Bristol Stool Form Scale (BSFS) or modified BSFS, and changes from baseline in constipation-related symptoms. Additional assessments include time to first bowel movement, use of rescue medication, and global and symptom-specific PRO measures.
Safety Evaluations Safety is monitored throughout the study by assessment of adverse events (AEs), clinical laboratory parameters, vital signs, physical examinations, and electrocardiograms (ECGs).
Gastrointestinal events, including diarrhea, are of particular interest due to the mechanism of action of plecanatide. Criteria for dose interruption or discontinuation are specified in the protocol for participants experiencing clinically significant adverse events.
Treatment-emergent adverse events, serious adverse events, and discontinuations due to adverse events will be summarized descriptively by treatment group.
Pharmacokinetic Assessments Pharmacokinetic evaluations include measurement of plasma concentrations of plecanatide and its metabolite at specified time points following dosing. Given the minimal systemic absorption observed in prior studies, PK analyses are exploratory and are intended to further characterize exposure in the pediatric population.
Statistical Considerations Approximately 30 participants per treatment group within each age cohort are planned. The sample size is considered sufficient for evaluation of the primary objective in this Phase 2b study.
The primary efficacy analysis will be performed on the intent-to-treat population using a mixed-effects model for repeated measures, including treatment group, time, and relevant baseline covariates. Secondary endpoints will be analyzed using appropriate statistical methods based on endpoint type.
Safety analyses will be performed on the safety population and will be summarized descriptively.
Data Collection and Study Conduct Study data are collected using electronic case report forms (eCRFs) and participant eDiaries. Compliance with study procedures, including study drug administration and diary completion, is monitored throughout the study.
The study is conducted in accordance with the principles of Good Clinical Practice (GCP), applicable regulatory requirements, and institutional review board or ethics committee approval. Written informed consent and, where applicable, assent are obtained prior to participation.
Inclusion Criteria:• Male or female children and adolescents aged 6 to \<18 years at time of consent.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive weight-based low-dose plecanatide administered orally once daily for 8 weeks.
Drug: plecanatide
Participants will receive weight-based high-dose plecanatide orally once daily for 8 weeks.
Drug: plecanatide
Participants will receive matching placebo orally once daily for 8 weeks.
Drug: Placebo
Plecanatide is administered orally once daily for 8 weeks. Participants receive weight-based dosing corresponding to assigned treatment arm (low-dose or high-dose) to achieve target exposure ranges. Tablets may be taken with or without food and may be swallowed whole or administered in an alternative form if necessary, as specified in the protocol.
Placebo tablets matching plecanatide in appearance are administered orally once daily for 8 weeks. Placebo is used to maintain blinding and is administered under the same conditions as active study drug.
Change From Baseline in Weekly Spontaneous Bowel Movement (SBM) Frequency at Week 8
Spontaneous bowel movements (SBMs) are defined as bowel movements that occur without the use of rescue medication within the preceding 24 hours. Weekly SBM frequency will be calculated based on daily electronic diary entries. The endpoint is the change from baseline in the number of SBMs per week at Week 8.
Time frame: Baseline to week 8
Proportion of Participants Who Are SBM Responders at Week 8
An SBM responder is defined as a participant who achieves an increase from baseline of ≥1 spontaneous bowel movement (SBM) per week. The proportion of responders will be assessed at Week 8 based on electronic diary data.
Time frame: week 8
Change From Baseline in Weekly Complete Spontaneous Bowel Movement (CSBM) Frequency at Week 8
Complete spontaneous bowel movements (CSBMs) are defined as SBMs associated with a sensation of complete evacuation. Weekly CSBM frequency will be calculated based on daily electronic diary entries. The endpoint is the change from baseline in the number of CSBMs per week at Week 8.
Time frame: Baseline to week 8
Change From Baseline in Stool Consistency as Measured by the Bristol Stool Form Scale (BSFS) at Week 8
Stool consistency will be assessed using the Bristol Stool Form Scale (BSFS) recorded in the electronic diary. Scores range from 1 (hard stools) to 7 (watery stools). The endpoint is the change from baseline in mean BSFS score at Week 8.
Time frame: Baseline to week 8
Time to First Spontaneous Bowel Movement (SBM)
Time to first spontaneous bowel movement (SBM) is defined as the time from first dose of study drug to the first SBM recorded in the electronic diary.
Time frame: up to 8 weeks
Use of Rescue Medication Over 8 Weeks
Rescue medication use is defined as the number of days participants use rescue medication (bisacodyl) due to lack of bowel movement. Use will be recorded daily in the electronic diary.
Time frame: Baseline and Weeks 1 through 8
Incidence of Treatment-Emergent Adverse Events (TEAEs)
A treatment-emergent adverse event (TEAE) is any adverse event that begins or worsens after the first dose of study drug through the end of the follow-up period.
Time frame: Up to 10 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Oct 2027, 14 months after the start.
Of 24 industry-sponsored phase 2 interventional studies under Constipation, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 29. This study's planned 14 months is below that.
Counting every sponsor, half of 41 studies reached it within 20 months; a quarter within 10 and three quarters within 42.
Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Aug 2026, on Oct 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Plecanatide
Bausch Health Americas, Inc. →